Ursodiol

CHEMBL1551 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

392.6 g/mol

LogP

4.9

Phase

4

Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring hydrophilic bile acid that reduces cholesterol saturation in bile by decreasing hepatic cholesterol secretion and absorption, and also exerts cytoprotective and anti-inflammatory effects on hepatocytes and cholangiocytes. It is approved for dissolving cholesterol gallstones, treating primary biliary cholangitis (PBC), and preventing gallstone formation after bariatric surgery, and is investigated in colorectal cancer prevention and other liver conditions. Its hepatoprotective mechanism involves displacement of toxic hydrophobic bile acids.

น้ำหนักโมเลกุล

392.6000 g/mol

LogP

4.90

TPSA

77.80 Å²

Lipinski RO5

ผ่าน

ด้านการรักษา

Rheumatoid Arthritis Parkinson's Disease Gastroesophageal Reflux Disease Non-Alcoholic Fatty Liver Disease Hyperlipidemia Obesity Type 2 Diabetes Hypertension Breast Cancer Hepatitis C Heart Failure Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1

Molecular Formula

C24H40O4

HBD / HBA

3 / 4

พันธะที่หมุนได้

4

อะตอมหนัก

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring hydrophilic bile acid that reduces cholesterol saturation in bile by decreasing hepatic cholesterol secretion and absorption, and also exerts cytoprotective and anti-inflammatory effects on hepatocytes and cholangiocytes. It is approved for dissolving cholesterol gallstones, treating primary biliary cholangitis (PBC), and preventing gallstone formation after bariatric surgery, and is investigated in colorectal cancer prevention and other liver conditions. Its hepatoprotective mechanism involves displacement of toxic hydrophobic bile acids.

Yes, Ursodiol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1551. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 31401. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Ursodiol บน PillFYI

โครงสร้าง

ข้อมูลด่วน

สูตร: C24H40O4
คำพ้องความหมาย: 5

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.